HCW Biologics (NASDAQ:HCWB – Get Free Report) and Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.
Institutional & Insider Ownership
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
HCW Biologics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
HCW Biologics presently has a consensus target price of $30.00, indicating a potential upside of 920.41%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 62.99%. Given HCW Biologics’ higher possible upside, research analysts plainly believe HCW Biologics is more favorable than Inhibrx Biosciences.
Profitability
This table compares HCW Biologics and Inhibrx Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
| Inhibrx Biosciences | N/A | -563.90% | -83.48% |
Earnings & Valuation
This table compares HCW Biologics and Inhibrx Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HCW Biologics | $50,000.00 | 108.19 | -$7.96 million | ($27.60) | -0.11 |
| Inhibrx Biosciences | $1.30 million | 1,372.02 | -$140.05 million | ($8.88) | -13.65 |
HCW Biologics has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
Inhibrx Biosciences beats HCW Biologics on 10 of the 15 factors compared between the two stocks.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
About Inhibrx Biosciences
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
